Faust, Tyler B.
Yoon, Hojong http://orcid.org/0000-0002-6062-5489
Nowak, Radosław P. http://orcid.org/0000-0002-0605-0071
Donovan, Katherine A. http://orcid.org/0000-0002-8539-5106
Li, Zhengnian
Cai, Quan
Eleuteri, Nicholas A.
Zhang, Tinghu
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Fischer, Eric S. http://orcid.org/0000-0001-7337-6306
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1F32CA232772-01, R01CA214608, 1F32CA232772-01)
Damon Runyon Cancer Research Foundation (DRR-50-18)
Article History
Received: 24 May 2019
Accepted: 2 September 2019
First Online: 4 November 2019
Competing interests
: E.S.F. is a founder and/or member of the scientific advisory board (SAB) and equity holder of C4 Therapeutics and Civetta Therapeutics, and a consultant to Novartis, AbbVie and Pfizer. The Fischer laboratory receives research funding from Novartis, Deerfield and Astellas. N.S.G. is a founder, scientific advisory board member and equity holder in Gatekeeper, Syros, Petra, C4, B2S and Soltego. The Gray laboratory receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Janssen, Kinogen, Voronoi, Her2llc, Deerfield and Sanofi. N.S.G., E.S.F, H.Y., Q.C., T.Z., T.F., R.P.N and K.A.D. are inventors on patent applications (PCT/US2018/065701 and PCT/US2019/014919) submitted by the Dana-Farber Cancer Institute.